Top

19-12-2023 | Nevi | ORIGINAL ARTICLE

Shedding light on PRAME expression in dysplastic nevi: a cohort study

Authors: Lorenzo Innocenti, Rosa Scarpitta, Serena Corraro, Valerio Ortenzi, Angelo G. Bonadio, Barbara Loggini, Katia De Ieso, Antonio G. Naccarato, Giuseppe N. Fanelli, Cristian Scatena

Published in: Virchows Archiv

Abstract

Dysplastic nevi represent one of the least agreed-upon entities in dermatopathology despite the existence of established criteria. This study explores preferentially expressed antigen in melanoma (PRAME) in dysplastic nevi, an uncharted area. We examined 22 common melanocytic nevi (CMN), 20 cutaneous melanomas (CM), 48 low-grade dysplastic nevi (LG-DN), and 40 high-grade dysplastic nevi (HG-DN). PRAME was immunohistochemically assessed using a five-tiered system (0 to 4 +). Among CMN, 59% scored 0, 32% scored 1 + , and 9% scored 2 + . CM had score 2 + and 4 + in 11% and 89% of cases, respectively. Among LG-DN, 38% presented score 0, 31% score 1 + , 17% score 2 + , 8% score 3 + , and 6% score 4 + . Thirty per cent of HG-DN demonstrated a score 0, 30% with score 1 + , 15% score 2 + , 10% score 3 + , and 15% score 4 + . Compared to CMN and CM, LG-DN and HG-DN showed heterogeneous expression profiles of PRAME. PRAME positivity effectively distinguished HG-DN from CM with 85% specificity and 80% sensitivity (p < 0.0001). Predictive values were 87% (negative) and 76% (positive). Furthermore, a trend of increased PRAME expression from LG-DN to HG-DN was observed. However, the applicability of PRAME in the differential diagnosis of dysplastic lesions remains unclear as can yield conflicting results with morphology, which remains the primary diagnostic tool for melanocytic lesions.

Available only for authorised users

Drozdowski R, Spaccarelli N, Peters MS, Grant-Kels JM (2023) Dysplastic nevus part I: historical perspective, classification, and epidemiology. J Am Acad Dermatol 88:1–10. https://doi.org/10.1016/j.jaad.2022.04.068CrossRefPubMed

Elder DE (2010) Dysplastic naevi: an update. Histopathology 56:112–120. https://doi.org/10.1111/j.1365-2559.2009.03450.xCrossRefPubMed

Shors AR, Kim S, White E et al (2006) Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma: dysplastic naevi and melanoma. Br J Dermatol 155:988–993. https://doi.org/10.1111/j.1365-2133.2006.07466.xCrossRefPubMed

Elder DE, Bastian BC, Cree IA et al (2020) The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144:500–522. https://doi.org/10.5858/arpa.2019-0561-RACrossRefPubMed

Aydin Ulgen O, Yıldız P, Acar HC, Demirkesen C (2022) Analysis of interobserver reproducibility in grading dysplastic nevi: results of the application of the 2018 World Health Organization grading criteria. J Cutan Pathol 49:343–349. https://doi.org/10.1111/cup.14165CrossRefPubMed

Nobre AB, Piñeiro-Maceira J, Raggio Luiz R (2013) Analysis of interobserver reproducibility in grading histological patterns of dysplastic nevi*. An Bras Dermatol 88:23–31. https://doi.org/10.1590/S0365-05962013000100002CrossRefPubMedPubMedCentral

Ikeda H, Lethé B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208. https://doi.org/10.1016/S1074-7613(00)80426-4CrossRefPubMed

Wadelin F, Fulton J, McEwan PA et al (2010) Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer 9:226. https://doi.org/10.1186/1476-4598-9-226CrossRefPubMedPubMedCentral

Liu Z, Li M, Jiang Z, Wang X (2018) A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol 11:311–329. https://doi.org/10.1016/j.tranon.2018.01.011CrossRefPubMedPubMedCentral

10.

Xu Y, Zou R, Wang J et al (2020) The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer. Cell Prolif 53. https://doi.org/10.1111/cpr.12770

11.

Šafanda A, Kendall Bártů M, Michálková R et al (2023) Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. Virchows Arch. https://doi.org/10.1007/s00428-023-03629-zCrossRefPubMed

12.

Hedrich V, Breitenecker K, Ortmayr G et al (2023) PRAME is a novel target of tumor-intrinsic Gas6/Axl activation and promotes cancer cell invasion in hepatocellular carcinoma. Cancers 15:2415. https://doi.org/10.3390/cancers15092415CrossRefPubMedPubMedCentral

13.

Kern CH, Yang M, Liu W-S (2021) The PRAME family of cancer testis antigens is essential for germline development and gametogenesis. Biol Reprod 105:290–304. https://doi.org/10.1093/biolre/ioab074CrossRefPubMed

14.

Schenk T, Stengel S, Goellner S et al (2007) Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46:796–804. https://doi.org/10.1002/gcc.20465CrossRefPubMed

15.

Epping MT, Wang L, Edel MJ et al (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847. https://doi.org/10.1016/j.cell.2005.07.003CrossRefPubMed

16.

Neuhaus N (2016) PRAME as diagnostic marker and as regulator for cell fate decisions in germ cell cancers. Br J Cancer 115:401–402. https://doi.org/10.1038/bjc.2016.217CrossRefPubMedPubMedCentral

17.

Alomari AK, Tharp AW, Umphress B, Kowal RP (2021) The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors. J Cutan Pathol 48:1115–1123. https://doi.org/10.1111/cup.14000CrossRefPubMed

18.

Lezcano C, Jungbluth AA, Nehal KS et al (2018) PRAME expression in melanocytic tumors. Am J Surg Pathol 42:1456–1465. https://doi.org/10.1097/PAS.0000000000001134CrossRefPubMedPubMedCentral

19.

Raghavan SS, Wang JY, Kwok S et al (2020) PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features. J Cutan Pathol 47:1123–1131. https://doi.org/10.1111/cup.13818CrossRefPubMed

20.

Fattori A, de la Fouchardière A, Cribier B, Mitcov M (2022) Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation. Hum Pathol 121:19–28. https://doi.org/10.1016/j.humpath.2021.12.008CrossRefPubMed

21.

Cazzato G, Cascardi E, Colagrande A et al (2022) PRAME immunoexpression in 275 cutaneous melanocytic lesions: a double institutional experience. Diagnostics 12:2197. https://doi.org/10.3390/diagnostics12092197CrossRefPubMedPubMedCentral

22.

Ricci C, Dika E, Ambrosi F et al (2022) Cutaneous melanomas: a single center experience on the usage of immunohistochemistry applied for the diagnosis. Int J Mol Sci 23:5911. https://doi.org/10.3390/ijms23115911CrossRefPubMedPubMedCentral

23.

Lohman ME, Steen AJ, Grekin RC, North JP (2021) The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. J Cutan Pathol 48:856–862. https://doi.org/10.1111/cup.13958CrossRefPubMed

24.

Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA (2021) PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 78:1000–1008. https://doi.org/10.1111/his.14312CrossRefPubMed

25.

Lezcano C, Pulitzer M, Moy AP et al (2020) Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol 44:503–508. https://doi.org/10.1097/PAS.0000000000001393CrossRefPubMedPubMedCentral

26.

Koch EAT, Erdmann M, Berking C et al (2023) Standardized computer-assisted analysis of prame immunoreactivity in dysplastic nevi and superficial spreading melanomas. Int J Mol Sci 24:6388. https://doi.org/10.3390/ijms24076388CrossRefPubMedPubMedCentral

27.

Zhu H, Wang J, Yin J et al (2018) Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of p53 mediated pathway. Cell Physiol Biochem 45:1121–1135. https://doi.org/10.1159/000487353CrossRefPubMed

28.

Kewitz S, Staege MS (2013) Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS ONE 8:e55897. https://doi.org/10.1371/journal.pone.0055897CrossRefPubMedPubMedCentral

29.

Borden ES, Adams AC, Buetow KH et al (2021) Shared gene expression and immune pathway changes associated with progression from nevi to melanoma. Cancers 14:3. https://doi.org/10.3390/cancers14010003CrossRefPubMedPubMedCentral

30.

Gassenmaier M, Hahn M, Metzler G et al (2021) Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas. Cancers 13:3864. https://doi.org/10.3390/cancers13153864CrossRefPubMedPubMedCentral

31.

Lezcano C, Jungbluth AA, Busam KJ (2020) Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. Am J Surg Pathol 44:893–900. https://doi.org/10.1097/PAS.0000000000001492CrossRefPubMedPubMedCentral

32.

Goto K, Yoshikawa S, Takai T et al (2023) Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: a study of 16 cases. J Cutan Pathol 50:739–747. https://doi.org/10.1111/cup.14470CrossRefPubMed

33.

Nasimi M, Ghanadan A, Kamyab K et al (2021) Prevalence and main determinants of BRAF V600E mutation in dysplastic and congenital nevi. Iran J Pathol 16:51–56. https://doi.org/10.30699/ijp.2020.130968.2451CrossRefPubMed

34.

Kiuru M, Tartar DM, Qi L et al (2018) Improving classification of melanocytic nevi: association of BRAF V600E expression with distinct histomorphologic features. J Am Acad Dermatol 79:221–229. https://doi.org/10.1016/j.jaad.2018.03.052CrossRefPubMedPubMedCentral

35.

Muse ME, Bergman DT, Salas LA et al (2022) Genome-scale DNA methylation analysis identifies repeat element alterations that modulate the genomic stability of melanocytic nevi. J Invest Dermatol 142:1893-1902.e7. https://doi.org/10.1016/j.jid.2021.11.025CrossRefPubMed

Title: Shedding light on PRAME expression in dysplastic nevi: a cohort study
Authors: Lorenzo Innocenti
Rosa Scarpitta
Serena Corraro
Valerio Ortenzi
Angelo G. Bonadio
Barbara Loggini
Katia De Ieso
Antonio G. Naccarato
Giuseppe N. Fanelli
Cristian Scatena
Publication date: 19-12-2023
Publisher: Springer Berlin Heidelberg
Keywords: Nevi
Melanoma
Melanoma
Published in: Virchows Archiv
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-023-03720-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Shedding light on PRAME expression in dysplastic nevi: a cohort study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content